Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Aggressive Non-Hodgkin Lymphoma
ALK-Positive Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Primary Mediastinal Large B-Cell Lymphoma
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Gray-Zone Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Biological: Rituximab
Drug: Prednisone
Drug: Etoposide
Drug: Doxorubicin
Drug: Cyclophosphamide
Procedure: Multigated Acquisition Scan
Biological: Glofitamab
Procedure: Echocardiography
Procedure: FDG-Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration

First Posted Date: 2020-01-18

Last Posted Date: 2024-09-30

Lead Sponsor: University of Washington

Target Recruit Count: 56

Registration Number: NCT04231877

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

Phase 2

Recruiting

Conditions: Primary Immune Deficiency Disorder
Immune Deficiency Disease
Bone Marrow Failure

Interventions: Drug: Alemtuzumab
Drug: Fludarabine
Drug: Melphalan
Radiation: Low Dose Total Body Irradiation
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2020-01-18

Last Posted Date: 2024-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT04232085

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Biological: CART-PSMA-TGFβRDN
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Anakinra

First Posted Date: 2020-01-13

Last Posted Date: 2023-08-21

Lead Sponsor: Tceleron Therapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT04227275

Locations: 🇺🇸
The University of Kansas Hospital, Kansas City, Kansas, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Stem Cell Transplantation in Crohn's Disease

Phase 1

Recruiting

Conditions: Crohn Disease

Interventions: Drug: Mesna
Drug: Cyclophosphamide
Drug: Filgrastim
Procedure: Apheresis catheter placement
Procedure: Leukapheresis
Drug: Fludarabine
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: anti-thymocyte globulin (rabbit)
Drug: lymphocyte immune globulin
Biological: Peripheral Blood Stem Cell Infusion
Drug: Cytoxan

First Posted Date: 2020-01-13

Last Posted Date: 2024-04-10

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 15

Registration Number: NCT04224558

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatinum
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2020-01-13

Last Posted Date: 2020-01-18

Lead Sponsor: AZ-VUB

Target Recruit Count: 63

Registration Number: NCT04224922

Locations: 🇧🇪
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
🇧🇪
Imelda Ziekenhuis, Bonheiden, Belgium
🇧🇪
Universitaire Ziekenhuis Antwerpen, Edegem, Belgium

and more 15 locations

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Phase 1

Recruiting

Conditions: Nodal Marginal Zone Lymphoma
Indolent Non-hodgkin Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Splenic Marginal Zone Lymphoma

Interventions: Drug: CAR.k.28
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2020-01-10

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04223765

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Phase 3

Recruiting

Conditions: High-Risk Neuroblastoma
Patient With Insufficient Response Chemoimmunotherapy

Interventions: Radiation: Radiotherapy
Drug: Vincristine
Drug: Busulfan
Drug: Dinutuximab Beta
Drug: Carboplatin
Drug: Melphalan
Drug: Etoposide
Drug: Thiotepa
Drug: Vindesine
Drug: Dacarbazine
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Temozolomide 100 MG
Drug: Irinotecan
Drug: Cyclophosphamid

First Posted Date: 2020-01-09

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT04221035

Locations: 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷
Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹
instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Phase 2

Withdrawn

Conditions: Recurrent T-Cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Recurrent Burkitt Lymphoma
Recurrent Aggressive Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma